

NCT02531971 Raw comparison:

Summary:
CHIA has 42 criteria while your personal folder has 45 criteria
Total found criteria: 42/42
Total not Found: 0/42
Total Extra: 3
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Men or non-pregnant women of any ethnic background │ Men or non-pregnant women of any ethnic background │
│ between the age of 18 and 45 years old             │ between the age of 18 and 45 years old             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects must be non-smokers (must have refrained  │ Subjects must be non-smokers (must have refrained  │
│ from the use of nicotine-containing substances     │ from the use of nicotine-containing substances     │
│ including tobacco products (e g cigarettes cigars  │ including tobacco products (e g cigarettes cigars  │
│ chewing tobacco gum patch or electronic            │ chewing tobacco gum patch or electronic            │
│ cigarettes) over the previous 2 months and are not │ cigarettes) over the previous 2 months and are not │
│ currently using tobacco products                   │ currently using tobacco products                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Provide written informed consent before initiation │ Provide written informed consent before initiation │
│ of any study procedures                            │ of any study procedures                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Available for follow-up for the planned duration   │ Available for follow-up for the planned duration   │
│ of the study                                       │ of the study                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to communicate well with the investigators    │ Able to communicate well with the investigators    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to adhere to the study protocol schedule      │ Able to adhere to the study protocol schedule      │
│ study restrictions and examination schedule        │ study restrictions and examination schedule        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who are within their ideal body weight    │ Subjects who are within their ideal body weight    │
│ (BMI between >17 and =28 kg/m2)                    │ (BMI between \>17 and ≤28 kg/m2)                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects deemed to be healthy as judged by the     │ Subjects deemed to be healthy as judged by the     │
│ Medically Accountable Investigator (MAI) and       │ Medically Accountable Investigator (MAI) and       │
│ determined by medical history physical examination │ determined by medical history physical examination │
│ and medication history                             │ and medication history                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects have no history of the following ongoing  │ Subjects have no history of the following ongoing  │
│ acute or intermittent pain postoperative pain      │ acute or intermittent pain postoperative pain      │
│ respiratory compromise acute or severe asthma or   │ respiratory compromise acute or severe asthma or   │
│ constipation (less than 1 bowel movement every 2   │ constipation (less than 1 bowel movement every 2   │
│ days)                                              │ days)                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Negative urine drug screening test at the time of  │ Negative urine drug screening test at the time of  │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have normal screening laboratories for white blood │ Have normal screening laboratories for white blood │
│ cells (WBC) hemoglobin (Hgb) platelets sodium      │ cells (WBC) hemoglobin (Hgb) platelets sodium      │
│ potassium chloride bicarbonate blood urea nitrogen │ potassium chloride bicarbonate blood urea nitrogen │
│ (BUN) creatinine ALT (liver function) AST (liver   │ (BUN) creatinine ALT (liver function) AST (liver   │
│ function) and bilirubin                            │ function) and bilirubin                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have normal screening laboratories for urine       │ Have normal screening laboratories for urine       │
│ protein and urine glucose                          │ protein and urine glucose                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female subjects must be of non-childbearing        │ Female subjects must be of non-childbearing        │
│ potential (as defined as surgically sterile [i e   │ potential (as defined as surgically sterile \[i e  │
│ history of hysterectomy or tubal ligation] or      │ history of hysterectomy or tubal ligation\] or     │
│ postmenopausal for more than 1 year [no bleeding   │ postmenopausal for more than 1 year \[no bleeding  │
│ for 12 consecutive months] or if of childbearing   │ for 12 consecutive months\] or if of childbearing  │
│ potential must be non-pregnant at the time of      │ potential must be non-pregnant at the time of      │
│ enrollment and on the morning of the first day of  │ enrollment and on the morning of the first day of  │
│ each study session and must agree to use hormonal  │ each study session and must agree to use hormonal  │
│ or barrier birth control such as implants          │ or barrier birth control such as implants          │
│ injectables combined oral contraceptives some      │ injectables combined oral contraceptives some      │
│ intrauterine devices (IUDs) sexual abstinence or a │ intrauterine devices (IUDs) sexual abstinence or a │
│ vasectomized parter                                │ vasectomized parter                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Agrees not to participate in another clinical      │ Agrees not to participate in another clinical      │
│ study/trial during the study period or to          │ study/trial during the study period or to          │
│ participate in an investigational drug study for   │ participate in an investigational drug study for   │
│ at least one month after last study session        │ at least one month after last study session        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Agrees not to donate blood to a blood bank         │ Agrees not to donate blood to a blood bank         │
│ throughout participation in the study and for at   │ throughout participation in the study and for at   │
│ least 3 months after last study day                │ least 3 months after last study day                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a normal ECG must not have the following to   │ Have a normal ECG must not have the following to   │
│ be acceptable pathologic Q wave abnormalities      │ be acceptable pathologic Q wave abnormalities      │
│ significant ST-T wave changes left ventricular     │ significant ST-T wave changes left ventricular     │
│ hypertrophy right bundle branch block left bundle  │ hypertrophy right bundle branch block left bundle  │
│ branch block (sinus rhythm is between 55-100 beats │ branch block (sinus rhythm is between 55-100 beats │
│ per minute)                                        │ per minute)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Temperature 35-37 9°C (95-100 3°F)                 │ Temperature 35-37 9°C (95-100 3°F)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Systolic blood pressure 90-140 mmHg                │ Systolic blood pressure 90-140 mmHg                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diastolic blood pressure 60-90 mmHg                │ Diastolic blood pressure 60-90 mmHg                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Heart rate 55-100 beats per minute                 │ Heart rate 55-100 beats per minute                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Respiration rate 12-18 breaths per minute          │ Respiration rate 12-18 breaths per minute          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are pregnant lactating or breast feeding │ Women who are pregnant lactating or breast feeding │
│ or have a positive serum pregnancy test at         │ or have a positive serum pregnancy test at         │
│ enrollment or positive urine pregnancy test on the │ enrollment or positive urine pregnancy test on the │
│ morning of the first day of any study session      │ morning of the first day of any study session      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Smokers (current use or use over the previous 2    │ Smokers (current use or use over the previous 2    │
│ months of nicotine-containing substances including │ months of nicotine-containing substances including │
│ tobacco products (e g cigarettes cigars chewing    │ tobacco products (e g cigarettes cigars chewing    │
│ tobacco gum patch or electronic cigarettes)        │ tobacco gum patch or electronic cigarettes)        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in any ongoing investigational drug  │ Participation in any ongoing investigational drug  │
│ trial/study or clinical drug trial/study           │ trial/study or clinical drug trial/study           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of chronic obstructive pulmonary disease   │ History of chronic obstructive pulmonary disease   │
│ or cor pulmonale or substantially decreased        │ or cor pulmonale or substantially decreased        │
│ respiratory reserve hypoxia hypercapnia or pre-    │ respiratory reserve hypoxia hypercapnia or pre-    │
│ existing respiratory depression                    │ existing respiratory depression                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active positive Hepatitis B C and HIV serologies   │ Active positive Hepatitis B C and HIV serologies   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive urine drug screening test                 │ Positive urine drug screening test                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of any prescription medication during the      │ Use of any prescription medication during the      │
│ session 0 to 30 days or over-the counter           │ session 0 to 30 days or over-the counter           │
│ medication e g antihistamines or topical           │ medication e g antihistamines or topical           │
│ corticosteroids (vitamin herbal supplements and    │ corticosteroids (vitamin herbal supplements and    │
│ birth control medications not included) during the │ birth control medications not included) during the │
│ session 0 to 3 days before entry to the study      │ session 0 to 3 days before entry to the study      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of medications or treatments that would        │ Use of medications or treatments that would        │
│ significantly influence or exaggerate responses to │ significantly influence or exaggerate responses to │
│ the test product or that would alter inflammatory  │ the test product or that would alter inflammatory  │
│ or immune response to the product or agents deemed │ or immune response to the product or agents deemed │
│ to be immunosuppressive as determined by physician │ to be immunosuppressive as determined by physician │
│ investigator with 72 hours prior to dosing (e g    │ investigator with 72 hours prior to dosing (e g    │
│ antihistamines systemic or topical corticosteroids │ antihistamines systemic or topical corticosteroids │
│ (within 3 weeks prior to dosing) cyclosporine      │ (within 3 weeks prior to dosing) cyclosporine      │
│ tacrolimus cytotoxic drugs immune globulin         │ tacrolimus cytotoxic drugs immune globulin         │
│ Bacillus Calmette-Guerin (BCG) monoclonal          │ Bacillus Calmette-Guerin (BCG) monoclonal          │
│ antibodies radiation therapy)                      │ antibodies radiation therapy)                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of monoamine oxidase inhibitors 21 days prior  │ Use of monoamine oxidase inhibitors 21 days prior  │
│ to study                                           │ to study                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current use of mixed agonist/antagonist (such as   │ Current use of mixed agonist/antagonist (such as   │
│ pentazocine nalbuphine or butorphanol) and partial │ pentazocine nalbuphine or butorphanol) and partial │
│ agonist (buprenorphine) analgesics                 │ agonist (buprenorphine) analgesics                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Current use of anticholinergics or other           │ Current use of anticholinergics or other           │
│ medications with anticholinergic activity          │ medications with anticholinergic activity          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Consumption of beverages containing alcohol        │ Consumption of beverages containing alcohol        │
│ grapefruit juice Seville oranges or quinine (e g   │ grapefruit juice Seville oranges or quinine (e g   │
│ tonic water) or foods containing poppy seeds in    │ tonic water) or foods containing poppy seeds in    │
│ the last 72 hours                                  │ the last 72 hours                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Donation or loss of greater than one pint of blood │ Donation or loss of greater than one pint of blood │
│ within 60 days of entry to the study               │ within 60 days of entry to the study               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any prior serious adverse reaction or              │ Any prior serious adverse reaction or              │
│ hypersensitivity to fentanyl morphine codeine      │ hypersensitivity to fentanyl morphine codeine      │
│ hydrocodone hydromorphone oxycodone oxymorphone    │ hydrocodone hydromorphone oxycodone oxymorphone    │
│ naltrexone or naloxone or any of the inactive      │ naltrexone or naloxone or any of the inactive      │
│ ingredients in the TDDS (polyester/ethyl vinyl     │ ingredients in the TDDS (polyester/ethyl vinyl     │
│ acetate polyacrylate adhesive silicone adhesive    │ acetate polyacrylate adhesive silicone adhesive    │
│ dimethicone NF or polyolefin)                      │ dimethicone NF or polyolefin)                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have a diagnosis of schizophrenia or other major   │ Have a diagnosis of schizophrenia or other major   │
│ psychiatric diagnosis or mental illness (e g major │ psychiatric diagnosis or mental illness (e g major │
│ depression)                                        │ depression)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medical history of personal drug or alcohol        │ Medical history of personal drug or alcohol        │
│ addiction or abuse                                 │ addiction or abuse                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any condition that would in the opinion of the MAI │ Any condition that would in the opinion of the MAI │
│ place the subject at an unacceptable risk of       │ place the subject at an unacceptable risk of       │
│ injury or render the subject unable to meet the    │ injury or render the subject unable to meet the    │
│ requirements of the protocol                       │ requirements of the protocol                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to communicate or cooperate with the     │ Inability to communicate or cooperate with the     │
│ investigators                                      │ investigators                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject has an obvious difference in skin color    │ Subject has an obvious difference in skin color    │
│ between arms or the presence of a skin condition   │ between arms or the presence of a skin condition   │
│ excessive hair at the application site (upper arm) │ excessive hair at the application site (upper arm) │
│ sunburn raised moles and scars open sore scar      │ sunburn raised moles and scars open sore scar      │
│ tissue tattoo or coloration that would interfere   │ tissue tattoo or coloration that would interfere   │
│ with placement of test articles skin assessment or │ with placement of test articles skin assessment or │
│ reactions to drug                                  │ reactions to drug                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Failure to pass opioid dependence challenge test   │ Failure to pass opioid dependence challenge test   │
│ on the first day study day of any study session (i │ on the first day study day of any study session (i │
│ e before taking the first dose of naltrexone       │ e before taking the first dose of naltrexone       │
│ hydrochloride) Each subject will be injected       │ hydrochloride) Each subject will be injected       │
│ subcutaneously with naloxone hydrochloride (0 8 mg │ subcutaneously with naloxone hydrochloride (0 8 mg │
│ injection) and will be observed for 45 minutes for │ injection) and will be observed for 45 minutes for │
│ signs and symptoms of opioid withdrawal            │ signs and symptoms of opioid withdrawal            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Within 4 weeks prior to dosing use of medications  │ Within 4 weeks prior to dosing use of medications  │
│ or treatments that would significantly influence   │ or treatments that would significantly influence   │
│ or exaggerate responses to the test product or     │ or exaggerate responses to the test product or     │
│ that would alter inflammatory or immune response   │ that would alter inflammatory or immune response   │
│ to the product or agents deemed to be              │ to the product or agents deemed to be              │
│ immunosuppressive as determined by physician       │ immunosuppressive as determined by physician       │
│ investigator                                       │ investigator                                       │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Have normal vital signs           │
├───────────────────────────────────┤
│ Must have maximum age of 45 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛